Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Summary

This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.

Timeline

Start

2022-12-20

Primary completion

2029-12

Completion

2029-12

Publications

• Robert M, Kotecki N, Gomez-Roca C, Massard C, Postel-Vinay S, Raimbourg J, Brandao M, Korakis I, Rouge TM, Comis S, Imadalou K, Chevalier C, Cordonnier L, Josse C, Teppaz G, Seite M, Durand J, Thepenier V, Mary C, Gauttier V, Derame M, Morello A, Poirier N, Cassier PA. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. Eur J Cancer. 2026 Jun 3;240:116729. doi: 10.1016/j.ejca.2026.116729. Epub 2026 Apr 9.

Drugs

Indications